9 Meters Biopharma Inc

-0.01 (-1.09%)
Earnings Announcements

9 Meters Biopharma Qtrly Loss Per Share $0.05

Published: 11/15/2021 13:34 GMT
9 Meters Biopharma Inc (NMTR) - Qtrly Loss per Share $0.05.
Quarter Ending Cash of $53.6 Million is Expected to Fund Operations Into 2023.
Larazotide Phase 3 for Celiac Disease Interim Analysis Expected in Q2 2022.
Phase 2 Vurolenatide Vibrant Study Enrollment Anticipated to Be Completed Before Year-end.
Q3 Earnings per Share View $-0.04 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.04

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.04

More details on our Analysts Page.